Access to POEMs and Essential Evidence Plus will no longer be included in CMA membership as of Dec. 1, 2023.
Clinical Question
Does pulmonary rehabilitation following hospitalization for exacerbation of chronic obstructive pulmonary disease affect mortality?
Bottom line
Initiation of pulmonary rehabilitation within 90 days of hospitalization for chronic obstructive pulmonary disease (COPD) exacerbation is associated with improved survival at 1 year compared with initiation after 90 days or not at all. However, enrollment in pulmonary rehabilitation is uncommon, likely due to a lack of physician referrals, a lack of available resources, and patient barriers to participation. 2b
Reference
Study design: Cohort (retrospective)
Funding: Government
Setting: Inpatient (any location) with outpatient follow-up
Synopsis
Patients hospitalized for COPD exacerbation have a high rate of health care utilization and an increased risk of mortality up to 1 year following discharge. Although current guidelines recommend pulmonary rehabilitation for patients within 4 weeks of hospitalization for COPD, few patients are enrolled. Using claims data from Medicare fee-for-service patients, these investigators identified 197,376 patients older than 65 years who were hospitalized for COPD. Of this cohort, only 2721 (1.5%) initiated pulmonary rehabilitation within 90 days of discharge, while the remaining either began pulmonary rehabilitation after 90 days or not at all. Patients who initiated within 90 days were younger, more likely to be men or non-Hispanic whites, live closer to a rehabilitation facility, and have fewer comorbidities. Propensity score matching was used to match 2710 patients from the 2 groups. In this matched cohort, initiating pulmonary rehabilitation within 90 days was associated with fewer deaths at 1 year (7.3% vs 14.1%; hazard ratio [HR] 0.50; 95% CI 0.42 - 0.59; number needed to treat = 15). Further, every 3 additional sessions of rehabilitation within the first 90 days were linked to a decreased risk of mortality (HR 0.91; 0.85 - 0.98).
Reviewer
Nita Shrikant Kulkarni, MD
Assistant Professor in Hospital Medicine
Northwestern University
Chicago, IL
Comments
none
none